Duke University MURDOCK Study

Duke, DCRI partner with Boehringer Ingelheim on new COPD study

April 27, 2017

Read the original article on Triangle Business Journal.

Duke University’s MURDOCK Study and Duke Clinical Research Institute (DCRI) will collaborate with Boehringer Ingelheim Pharmaceuticals on a new chronic obstructive pulmonary disease (COPD) study.

Based in Kannapolis, MURDOCK stands for the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis. The new study will involve following 850 participants over the course of five years and will be aimed at a achieving a better understanding of COPD progression, according to Duke and Boehringer Ingelheim.

“COPD remains a major public health problem, with respiratory disease now the third leading cause of death in the U.S. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide a framework for stratifying disease severity and prognosis. However, the GOLD classifications have only limited validation in COPD patient populations,” Dr. Scott Palmer, principal investigator of the MURDOCK COPD Study, said in an email.

Kristin Newby, MD

“Therefore, we sought to leverage the strength of the MURDOCK study, led by Dr. Kristin Newby and an outstanding study team in Kannapolis, to create an opportunity to validate the importance of the GOLD classifications in a real-world patient population in North Carolina,” he added.

The study will also allow for improved understanding of “the extent to which current treatment guidelines are followed in practice.” While the new COPD study will have wide-ranging importance when it comes to COPD research, it will be particularly important for the state of North Carolina, he said.

In the Triangle, DCRI employs more than 1,100 people, according to Triangle Business Journal research. Boehringer Ingelheim Pharmaceuticals is a U.S. subsidiary of Germany’s Boehringer Ingelheim Corporation, which had net sales of approximately $15.8 billion in 2015.

“Duke and the Duke Clinical Research Institute (DCRI) have a longstanding collaboration with BI around the study of another lung disease, idiopathic pulmonary fibrosis, or IPF. Our collaboration with BI led to the creation of the ongoing Idiopathic Pulmonary Fibrosis Outcomes Registry (IPF-PRO), representing a unique academic-industry partnership,” said Palmer.

“Based on the successful IPF-PRO model and a mutual interest in the study of COPD, DCRI and BI developed the COPD MURDOCK study,” he said.

Comments are closed.

Connect With Us